Logo

IVF

NAYA Biosciences, Inc. Common Stock

IVF

NAYA Biosciences, Inc. Common Stock • NASDAQ
$0.33 ▼ -0.03% (-0.00)
Market Cap $303452
52w High $37.44
52w Low $0.28
Dividend Yield 0%
P/E -0.01
Volume 33.04K
Outstanding Shares 928.27K

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $1.757M ▼ $2.265M ▼ $-2.645M ▲ -150.511% ▲ $-0.77 ▲ $-1.499M ▲
Q2-2025 $1.864M ▲ $3.76M ▼ $-5.285M ▲ -283.575% ▲ $-39.9 ▲ $-2.818M ▲
Q1-2025 $1.637M ▼ $17.7M ▲ $-17.404M ▼ -1.063K% ▼ $-56.22 ▼ $-16.858M ▼
Q4-2024 $1.686M ▲ $4.704M ▲ $-3.623M ▼ -214.921% ▼ $-9.04 ▼ $-3.214M ▼
Q3-2024 $1.433M $1.745M $-1.631M -113.782% $-5.04 $-1.097M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $355.891K ▼ $18.832M ▼ $12.983M ▼ $5.849M ▲
Q2-2025 $549.181K ▼ $19.319M ▼ $16.688M ▼ $2.631M ▼
Q1-2025 $840.407K ▲ $31.744M ▼ $28.409M ▼ $3.335M ▼
Q4-2024 $741.396K ▲ $46.449M ▲ $33.702M ▲ $12.747M ▲
Q3-2024 $471.591K $17.019M $17.043M $-23.316K

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.645M ▲ $-1.777M ▼ $-8.062K ▲ $1.591M ▲ $-193.29K ▲ $-1.785M ▼
Q2-2025 $-5.285M ▲ $-1.718M ▲ $-15.446K ▼ $1.442M ▼ $-291.226K ▼ $-1.726M ▲
Q1-2025 $-17.404M ▼ $-3.546M ▼ $-14.65K ▼ $3.659M ▲ $99.011K ▼ $-3.56M ▼
Q4-2024 $-3.623M ▼ $-617.379K ▲ $393.134K ▲ $494.05K ▲ $269.805K ▲ $-696.253K ▼
Q3-2024 $-1.631M $-640.807K $0 $169.464K $-471.343K $-640.807K

Five-Year Company Overview

Income Statement

Income Statement IVF looks like a very early‑stage, essentially pre‑revenue business. Reported sales over the past several years are negligible, while operating costs have been steady, leading to recurring net losses every year. The extremely large swings in reported earnings per share mostly reflect changes in share count and reverse splits rather than changes in the underlying business. Overall, this is a company still in build‑out mode, not yet in a phase where its income statement shows meaningful commercial traction or profitability.

Balance Sheet

Balance Sheet The balance sheet is very small and thinly capitalized, with only a modest base of total assets and very limited cash on hand. Equity is minimal and there is now some debt in the structure, suggesting rising financial leverage from a very small base. The long history of reverse stock splits points to past share price pressure and dilution as the company has tried to fund its activities. Altogether, the balance sheet signals a fragile financial position that leaves little room for operational setbacks without additional external financing.

Cash Flow

Cash Flow Cash generation from the core business has been weak to negative, which is typical for a company still developing and rolling out its model. Operating cash flows have not been sufficient to fund the business on their own, and while capital spending has been negligible, the company is still dependent on outside capital to keep going. This pattern underlines a key risk: until the fertility operations scale meaningfully, the company’s cash needs are likely to remain higher than the cash it produces internally.

Competitive Edge

Competitive Edge IVF’s edge centers on the INVOcell device and the intravaginal culture procedure, which promise a more natural and potentially more affordable alternative to traditional IVF. The strategy of owning and operating its own fertility clinics could deepen patient relationships and make it easier to standardize and promote its technology. On the positive side, fertility demand is rising and policy support for broader access is improving. On the risk side, the company is small and competing in a market with well‑established IVF providers, strong clinical brands, and significant marketing muscle. Success will depend on convincing both patients and clinicians that the INVOcell approach offers comparable outcomes at a lower cost, and on executing clinic expansion without overextending limited resources.

Innovation and R&D

Innovation and R&D Innovation is a clear bright spot. INVOcell is a proprietary, FDA‑cleared device built around a different way to perform assisted reproduction, shifting early embryo development into the woman’s body rather than a lab. This is differentiated technology with intellectual property protection and a clear focus on reducing cost and improving access. Future innovation appears to be more about scaling the clinic network, refining the procedure, and potentially developing next‑generation versions of the device rather than about a broad, expensive research pipeline. That keeps the story focused and targeted, but also concentrates the company’s fortunes on the long‑term adoption of a single core platform.

Summary

IVF is a very early‑stage, highly specialized fertility platform built around a unique device and procedure, operating with a very small financial base and no meaningful revenue yet. The strategic logic is straightforward: use a proprietary, lower‑cost technology and an integrated clinic model to tap into strong, growing demand for fertility care and improve access for patients priced out of traditional IVF. The main opportunities lie in market growth, policy tailwinds, and the potential for INVOcell to carve out a niche as a more affordable alternative. The main risks lie in the company’s thin balance sheet, persistent losses, dependence on outside funding, and the challenge of scaling a differentiated but unproven model in a competitive, clinically conservative market. Outcomes are highly uncertain and will hinge on execution, real‑world clinical acceptance, and the company’s ability to maintain financial flexibility during its build‑out phase.

NEWS

November 28, 2025 · 1:05 PM UTC

INVO Fertility Announces Intent to Acquire Indiana-Based Fertility Clinic “Family Beginnings”

Read more

November 25, 2025 · 9:00 AM UTC

INVO Fertility Announces a 1:8 Reverse Stock Split Effective Pre-Market Opening on November 28, 2025

Read more

November 17, 2025 · 8:30 AM UTC

INVO Fertility Announces Third Quarter 2025 Financial Results

Read more

October 27, 2025 · 8:30 AM UTC

INVO Fertility Partners with Heidi Health to Bring AI-Powered Tools to INVO's Wisconsin Fertility Institute

Read more

September 29, 2025 · 5:30 PM UTC

INVO Fertility to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Read more